FOS and diffuse large B-cell lymphoma: Here, most importantly, the sensitivity of DLBCL cells against HDACi was enhanced after knocking down c‐FOS by RNAi or the inhibition of the DNA binding capacity of c‐FOS with the compound T‐5224 and the more broadly acting agent difluorobenzocurcumin (CDF) (Figure 1B).